Announcement PDF ASX Announcement Pro-Rata Non-Renounceable Entitlement Offer - Extension of Closing Date Sydney Australia, 30 April 2025: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company), the Company developing a New Class of Synthetic Anti-Infectives, refers to the pro-rata non-renounceable entitlement offer of one (1) New Share for every six (6) existing Shares held by Eligible Shareholders at an issue price of $0.28 per New Share to raise up to $10.8 million (before costs) announced on 10 April 2025 (Entitlement Offer). Capitalised terms not defined in this notice have the meaning given to them in the Offer Booklet dispatched to Eligible Shareholders and lodged with ASX on 22 April 2025. Extension of Closing Date To provide additional time and opportunity for Eligible Shareholders to participate in the Entitlement Offer, the Company has decided to extend the closing date for the Entitlement Offer to 5:00pm (AEST) Friday, 9 May 2025. The Company reminds Eligible Shareholders who subscribe for their full Entitlement that they may also apply for Additional Shares in accordance with the Shortfall Offer. Further details about the Entitlement Offer, including how to participate and apply for Additional Shares is set out in the Offer Booklet. Revised Timetable The revised indicative timetable for the remaining dates of the Entitlement Offer is set out below: Event Last day to extend the Closing Date Entitlement Offer closes (5:00pm AEST) (Closing Date) Date* Tuesday, 6 May 2025 Friday, 9 May 2025 Securities quoted on a deferred settlement basis Monday,12 May 2025 Last day to announce results of Entitlement Offer Friday, 16 May 2025 Issue of New Shares under the Entitlement Offer Friday, 16 May 2025 Quotation of New Shares under the Entitlement Offer Monday, 19 May 2025 Last date to issue remaining Shortfall shares (if any) Friday, 8 August 2025 *Note: This timetable is indicative only and subject to change. The Company reserves the right to vary the above dates and times, subject to the ASX Listing Rules and the Corporations Act. If you have any query or question about the Entitlement Offer, please contact the Share Registry on 1300 288 664 (within Australia), or +61 2 9698 5414 (international) between 8:30 am and 7:00pm (AEST) Monday to Friday or by email at hello@automicgroup.com. This announcement has been approved for release by Recce Pharmaceuticals Board. About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic AntiInfectives designed to address the urgent global health problems of antibiotic-resistant superbugs. Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer antiinfectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics. The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development. Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s antiinfective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.